Key Takeaways
- Breast cancer treatment research is shifting away from traditional chemotherapy toward targeted hormone-based therapies that focus on blocking cancer growth signals more precisely.
- Most breast cancers are hormone receptor-positive, meaning they rely on hormones like estrogen to grow, which is why hormone therapies are now a major focus in clinical research.
- At NHO Revive, current clinical trials are centered on next-generation targeted therapies rather than standard chemotherapy approaches.
- Selective Estrogen Receptor Degraders (SERDs) are a key area of study, designed not only to block estrogen signals but also to break down estrogen receptors on cancer cells.
- CDK-targeting therapies are being evaluated to better control how quickly breast cancer cells divide, especially in advanced or metastatic cases.
- Combination treatment strategies are also being explored to improve outcomes for patients whose disease has progressed after earlier lines of therapy.
- Overall, these trials aim to offer more personalized treatment options that may improve effectiveness while also reducing the risk of severe side effects often seen with older treatment approaches.
The way we treat breast cancer is changing fast. Today, the most exciting breakthrough research isn’t focused on standard chemotherapy. Instead, it is all about targeted hormone therapies. These smart treatments focus directly on the specific signals that tell cancer cells to grow, aiming to block them without harming healthy cells the way traditional chemo does. At NHO Revive, we help patients explore potential new treatment options through clinical trials.
In this blog, we will break down exactly what breast cancer treatments we are studying at our site right now. We will explain how they work, who they might help, and exactly where you can find more information to help you or a loved one take the next step.
Why Hormone-Pathway Treatments Are Leading Breast Cancer Research Right Now
For decades, the word “cancer” immediately brought to mind traditional chemotherapy. But today, science is moving in a much gentler, smarter direction.
Why Breast Cancer Treatment Is Changing
The main reason for this shift is that the vast majority of breast cancers are hormone receptor-positive. This means the cancer cells use normal hormones, like estrogen, as fuel to grow and multiply.
How Treatments Are Targeting the Cancer’s Fuel Source
Instead of using heavy chemo to target all fast-growing cells in the body, the most significant medical breakthroughs are happening by simply shutting down this specific fuel supply. These targeted therapies find the precise hormone pathways the tumor relies on and disrupt them, effectively stopping the cancer from spreading while sparing your healthy cells.
If you are exploring clinical trials, this approach brings a major sense of relief. None of the four breast cancer trials currently active at NHO Revive involve traditional chemotherapy. Every single one is a targeted approach. By focusing entirely on these next-generation hormone therapies, these trials aim to offer effective, powerful solutions with fewer of the harsh side effects usually associated with cancer care.
Treatments Currently Being Evaluated at NHO Revive
Here are the four breast cancer studies currently active at NHO Revive and the treatments being investigated in each.
A Potential New Option for Early Breast Cancer
What it is:
This study tests an oral Selective Estrogen Receptor Degrader (SERD). Instead of simply blocking estrogen signaling, it binds to estrogen receptors and leads to their breakdown, cutting off the cancer’s growth signal.
Who it is for:
It includes patients with ER-positive, HER2-negative, node-positive early breast cancer who have already completed several years (typically 2–5 years) of standard endocrine therapy and remain at high risk of recurrence.
Why it matters:
The study explores whether switching to or continuing with a more targeted estrogen-receptor–degrading therapy can better reduce recurrence risk in patients who have already undergone standard treatment but still face ongoing risk.
Status: Currently enrolling at NHO Revive.
A Next-Generation Hormone Therapy for Early Breast Cancer
- What it is: An investigational next-generation oral Selective Estrogen Receptor Degrader (SERD). Researchers are studying whether an investigational drug can reduce the risk of breast cancer recurrence and improve long-term outcomes compared with standard hormone therapy in people with ER-positive, HER2-negative early breast cancer.
- Who it is for: This trial is for individuals with ER-positive, HER2-negative (ER+/HER2−) early breast cancer who have completed surgery, show no current evidence of disease, but have an intermediate-to-high risk of recurrence.
- Why it matters: Researchers are studying whether a study drug can improve outcomes and reduce the risk of breast cancer recurrence compared with standard endocrine therapy in people with ER-positive, HER2-negative early breast cancer.
- Status: Currently enrolling at NHO Revive.
A More Targeted CDK4 Inhibitor for Metastatic Breast Cancer
- What it is: A new oral treatment being studied alongside hormone therapy for advanced or metastatic HR-positive, HER2-negative breast cancer. This study is comparing the investigational treatment with commonly used standard therapies to evaluate its effectiveness and safety.
- Who it is for: It is for patients newly diagnosed with advanced or metastatic HR-positive, HER2-negative (HR+/HER2−) breast cancer who have not yet received any whole-body (systemic) treatment for their metastatic disease.
- Why it matters: This study is comparing a potential new oral treatment with current standard therapies to see if it can improve outcomes in advanced or metastatic breast cancer.
- Status: Currently enrolling at NHO Revive.
Targeting Multiple Pathways in Metastatic Breast Cancer
- What it is: This is a Phase 3 clinical trial testing a combination of an IV treatment with standard hormone therapy, with or without an additional targeted therapy. The study is looking at whether using these treatments together can better control advanced breast cancer compared to current approaches.
- Who it was for: People with advanced or metastatic HR-positive, HER2-negative breast cancer whose disease has progressed after previous standard treatments.
- Why it matters: This combination represents the next step forward for individuals who have already tried standard targeted therapies and are looking for new, effective options when current choices feel limited.
- Status: Enrollment is now closed, but active study procedures and patient monitoring remain ongoing at NHO Revive.
If any of these treatments sound relevant to your situation — or a loved one’s — the NHO Revive team is the right first call. We’re currently enrolling for three breast cancer studies in Lincoln, Nebraska. [See if you qualify →]
Conclusion:
In conclusion, breast cancer research continues to move toward more personalized and targeted treatment approaches. Through ongoing clinical trials, NHO Revive is helping to evaluate potential new therapies designed to improve outcomes. These studies may offer additional investigational options for individuals seeking innovative approaches to breast cancer care and may help shape future standards of treatment.
Frequently Asked Questions
What is a SERD, and how is it used in breast cancer treatment?
A Selective Estrogen Receptor Degrader (SERD) is a type of hormone therapy that blocks and breaks down estrogen receptors on breast cancer cells. SERDs are primarily used to treat HR-positive breast cancer, helping slow or stop cancer growth by reducing the cancer cells’ ability to use estrogen.
What is the difference between a CDK4 inhibitor and a CDK4/6 inhibitor?
A CDK4 inhibitor targets only the CDK4 protein, while a CDK4/6 inhibitor blocks both CDK4 and CDK6 proteins. CDK4/6 inhibitors are more commonly used in HR-positive, HER2-negative breast cancer because they help prevent cancer cells from dividing and multiplying.
Can I join a breast cancer clinical trial if I'm already on hormone therapy?
Yes, many breast cancer clinical trials allow patients who are currently receiving or have previously received hormone therapy. Eligibility requirements vary by study, so researchers will review your treatment history, cancer type, and overall health to determine whether you qualify.
What does HR+/HER2− breast cancer mean?
HR+/HER2− breast cancer refers to a cancer that is hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2−). This means the cancer grows in response to hormones such as estrogen or progesterone but does not overexpress the HER2 protein. It is one of the most common breast cancer subtypes.
Are any new breast cancer treatments available through clinical trials in Nebraska?
Yes, clinical trials in Nebraska may provide access to investigational breast cancer treatments, including hormone therapies, targeted therapies, immunotherapies, and combination treatments. Available studies change over time, so patients should consult a research center or healthcare provider to learn about current trial opportunities and eligibility requirements.
